Currently, PARPi Olaparib and Talazoparib have gained approvals for the therapy of metastatic or locally advanced gBRCA-mutant or HER-2 negative breast cancer from the Food and Drug Administration after the basis of Phase III clinical trials (40, 42). This evidence concerns the gene ERBB2 and breast carcinoma.